Cibc World Markets Corp lifted its stake in Bristol-Myers Squibb (NYSE:BMY – Free Report) by 16.3% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 319,945 shares of the biopharmaceutical company’s stock after buying an additional 44,772 shares during the quarter. Cibc World Markets Corp’s holdings in Bristol-Myers Squibb were worth $18,096,000 as of its most recent SEC filing.
Several other hedge funds and other institutional investors have also recently bought and sold shares of BMY. Raymond James Financial Inc. acquired a new stake in shares of Bristol-Myers Squibb during the 4th quarter worth approximately $257,618,000. FMR LLC grew its position in Bristol-Myers Squibb by 10.5% during the third quarter. FMR LLC now owns 44,940,609 shares of the biopharmaceutical company’s stock valued at $2,325,227,000 after buying an additional 4,275,787 shares during the period. Jennison Associates LLC increased its holdings in Bristol-Myers Squibb by 420.1% in the third quarter. Jennison Associates LLC now owns 4,241,255 shares of the biopharmaceutical company’s stock valued at $219,443,000 after buying an additional 3,425,789 shares in the last quarter. Janus Henderson Group PLC raised its position in shares of Bristol-Myers Squibb by 695.1% in the third quarter. Janus Henderson Group PLC now owns 3,554,758 shares of the biopharmaceutical company’s stock worth $183,971,000 after acquiring an additional 3,107,672 shares during the period. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its stake in shares of Bristol-Myers Squibb by 18.7% during the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 19,074,823 shares of the biopharmaceutical company’s stock worth $986,931,000 after acquiring an additional 3,002,418 shares in the last quarter. 76.41% of the stock is owned by institutional investors and hedge funds.
Insiders Place Their Bets
In other Bristol-Myers Squibb news, EVP Samit Hirawat acquired 1,823 shares of the business’s stock in a transaction that occurred on Friday, February 14th. The stock was purchased at an average cost of $54.84 per share, with a total value of $99,973.32. Following the transaction, the executive vice president now owns 63,932 shares of the company’s stock, valued at $3,506,030.88. This trade represents a 2.94 % increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. 0.09% of the stock is owned by insiders.
Analysts Set New Price Targets
Read Our Latest Research Report on BMY
Bristol-Myers Squibb Stock Up 1.8 %
Shares of BMY opened at $60.07 on Tuesday. Bristol-Myers Squibb has a 52-week low of $39.35 and a 52-week high of $63.33. The company has a quick ratio of 1.15, a current ratio of 1.25 and a debt-to-equity ratio of 2.90. The stock has a fifty day simple moving average of $57.87 and a two-hundred day simple moving average of $55.69. The company has a market capitalization of $121.89 billion, a PE ratio of -13.59, a price-to-earnings-growth ratio of 2.07 and a beta of 0.43.
Bristol-Myers Squibb (NYSE:BMY – Get Free Report) last issued its earnings results on Thursday, February 6th. The biopharmaceutical company reported $1.67 EPS for the quarter, topping analysts’ consensus estimates of $1.47 by $0.20. Bristol-Myers Squibb had a negative net margin of 18.53% and a positive return on equity of 13.93%. As a group, equities analysts forecast that Bristol-Myers Squibb will post 6.74 EPS for the current year.
Bristol-Myers Squibb Announces Dividend
The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, May 1st. Investors of record on Friday, April 4th will be given a $0.62 dividend. The ex-dividend date is Friday, April 4th. This represents a $2.48 annualized dividend and a yield of 4.13%. Bristol-Myers Squibb’s payout ratio is -56.11%.
Bristol-Myers Squibb Profile
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.
Read More
- Five stocks we like better than Bristol-Myers Squibb
- Growth Stocks: What They Are, Examples and How to Invest
- Can TikTok Stock Picks Really Make You Rich?
- How to trade using analyst ratings
- The “Quality” Rotation: Back to Basics Investing
- Insider Trades May Not Tell You What You Think
- Occidental Petroleum: 4 Reasons to Love These Prices
Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.